and Thank Eleanor, good you, morning, everyone.
strategic point we realize are readouts for The we $X.X third revenue clinical as resourced in approximately turning meaningful clinical XXXX our each fully of to Insmed, and billion major of now secured trial With four from trial financing. pillars. quarter a marked growth, advanced numerous enrollment, capital,
from fourth frontline addition Phase X Collectively, from company. TPIP, our we anticipated and these from filings, clinical NTM bronchiectasis, IND pillar. transform in will our program, Brensocatib the preclinical and in believe readouts data data to Specifically, data
on a the financing. take updates moment pillars, I our recent detailed providing discuss to Before four want to
markets, our This the strategically the recent not announced of capital in protect been one achieve ourselves any and week against position the geopolitical raise macroeconomic when that four to our company. on Rather, a As us enviable stronger a said and more transactions, was some we as our pillars. to underlying environments in advance of change the in never financing in of we position as needed we I weigh market difficult continue mitigate way. the backdrop does last financing rationale to it places have of the objectives, strategic ambitious risks an to to The history. strategy
us Our have meaningful place that the and this look to financial financing we feel when and each support, aim past be very of in we the catalyst us strong of will what updating in was future the company our good to catapult pillars. on should be positive future results the and from of here. transactions. from takeaway will forward progress you We these our four message about hope position this We these concerns, a
detail, but the COVID despite more key revenues. our results and this revenue quarter the contributed Sara the third growth headwinds in saw ARIKAYCE We global will in US, foreign to still global strong. cover is performance. back takeaway exchange Turning and continued revenue to meaningfully Japan, in quarter's that were region
bronchiectasis, ARIKAYCE and ARIKAYCE the UK, in very for the decision, the of in remain I now if performance all Brensocatib for NTM, ARIKAYCE potential of globally, recently approved. as Netherlands, the Italy, pleased England. commercial even we be for launched and team additional With underway preparations favorable including are well with Belgium. as this already commercially will launches, Frontline Europe, reimbursement to secured Turning in a for approval as Germany, parts
of our and starting believe ENCORE, running each MAC more provide parallel. from detail clinical with which me of ARIKAYCE results Frontline the Now, trials let four trials, the in global program, these if ARISE In patients. patients activities US pillars, within two of favorable, ARIKAYCE will two the geographies, on MAC We XXX,XXX, development Japan, in consists with respectively. XXX,XXX, clinical support full our number largest FDA is diagnosed for international the approvals and NTM and approximately newly select of diagnosed NTM, newly
complete the appropriate in enrolled to ahead addressable expansion work the those be Screening to last we and should in two into that of anticipate is ARISE market. nearly the calculation, a by which now the Frontline refine we We increase secure am treatment, slightly would I pleased While trial, are weeks, any our schedule. who current complete. for approval, in next in ARISE will patient frontline report represent enrollment is immediate multifold is
ARISE the the Let that me ARISE commentary to over XXXX. of goal expect valid first, of of and data the can some on course half a results. end We you responsive. anticipate provide of from what demonstrate data year. We PRO the is, the data the trial first range anticipate ARISE from remind our To you, with these is sharing by next
remain we essentially examine signs second the the the We With and pace as using you XXXX, sharing in early data updating will important to move pace the the look as ARISE PRO, anticipate of forward non-treatment track suggesting entire forward. before and these enrollment Next, complete, well treatment on culture we of end be half anticipate conversion, we other the measures. enrollment trial with ENCORE will dataset, case. comparing We of on the enrollment complete to the of accelerate, and as arms XXXX. in to enrollment the ENCORE in this
frontline ENCORE. the in program. opportunity clear readout, the will of hope data, this we registrational look a adjustments We our be increasing forward to of necessary and on data we success before likelihood ENCORE, do study. the of updating understanding Should to in the our with have likely have time ARISE to so performance the Additionally, to you progress
enormous believe to turn a be thereby I'll a in DPP-X we successful, treat landscape. pipeline diseases, an anti-inflammatory neutrophil-mediated a to treatment potential Brensocatib, the potential of oral an groundbreaking array pillar, second now representing addition believe that could If our Brensocatib to inhibitor product. has we
are of second to in of enrollment us quarter platform separate mind, Starting of and from the next without our our Phase or a first-in-mechanism to topline ASPEN clinically, polyps, target quarter rhinosinusitis bronchiectasis, four trial the enrollment expectation CRS, we indications cystic and pace with settled approach, CF, of continues, to of We pursue estimate in chronic or this X end working suppurativa, year. fibrosis, first share the HS. nasal around upon initially With of bronchiectasis, giving build or in XXXX. hydradenitis data our encouraging before in this excited completing the are the ASPEN trial confidence have
indications at points, these and of benefit NTM, much Japan. between leverage bronchiectasis report study a million planned. to meeting and Board, the launch from bronchiectasis, is third key three by between expect significant, to and the should in Data In or than that as approximately addition, in determined the commercial the approved and Monitoring plan patients of that target in DSMB, occurred the these to continue synergies authorities geographies, earlier the I US, was indications. X Safety we opportunity it pleased the If where ASPEN call treating is this am regulatory week Though infrastructure overlap able are broader bronchiectasis use be we to Brensocatib for Europe,
for the year and turn end now X opportunity, CFTR second with patients the reduction me of is both not diagnosed CFTR Phase on CF advancing modulators, patients estimated to on sizable Brensocatib, by an as total population. indication XX,XXX fibrosis. that PKPD Let data planned, remain modulators. exacerbations this this nothing worldwide, on to and of potential The another and for Recall topline track market to study cystic in we have approved those represents treat
two As shared, further for HS. we and previously CRS have identified clinical development, indications
ASPEN increase results approved is another cannot plan NTM their We from treatment. addressed the the the thereafter. these will be pacing in we where believe We Importantly, in could order Phase that condition burn to represent await of balance medical a cash studies the would for of need middle nothing by mindfully like follow be potential the CRS overstated. they unmet We're against enormity HS study. while in Brensocatib, CRS study there start X in to XXXX. is bronchiectasis,
could indications for the patients market millions of to addressable potentially program. Additional add this
pulmonary Our studies will anticipate Both to third development associated enter pillar with pace and is for lung their as accelerate we TPIP, patients hypertension PAH. interstitial pulmonary trials disease and sites. X open or PHILD, a of treprostinil We in prodrug both or Phase XXXX. hypertension, are enrollment arterial continuing enrolling
to potential space. our and patients a it the long-term turn pillar, This cost Medicine. this gene to generate for pillar, doing in become technology From to addition one strategic on average increasingly fourth a multifold. intend next are this will rare lower as I'll we in disease The compounds the work of year impact in to we profound reflects would Translational with the we methods important platforms manufacturing several therapy to to per the Insmed's pillar produce two that, group, gene years. pillar vision, world-class on now successful, if novel expect to therapies includes INDs have
landscape, intelligence gene are and could using Collectively, us believe we caps redose deimmunize used and technologies, successful, patients. to result we therapy, reduced safer progress attempt dose enabling if in patients significantly advanced actual artificial the potentially addition, costs. therapies engineering the gene more with and to making to at capabilities AAV therapy transform In in to protein effective these
redosing. unrelated pursuing proteins, where from benefit have also gene therapy, patients therapeutic deimmunized we would Finally, specific to efforts ongoing
you. are more We we into delve details research with where planning a day will
achieving over finalizing sharing of take to never to one We companies. all We the the efforts next is believe great date making next the great on ambition biotechnology teams world we Insmed these to of like the more are behind in look advancing coming operate, technologies four we a progress We before. first year. our months. where the and in for around that pillars are half and place Across forward build
for over Let me her the Sara call commentary. turn now to
